Published Clinical Trials
Read detailed study abstracts, clinical trial methodology, and verified findings regarding psilocybin neuro-regenerative standards.
Psilocybin for Treatment-Resistant Depression: A Randomized Clinical Trial
This landmark clinical trial evaluated the efficacy of isolated psilocybin compounds in treating clinical depression. Results demonstrated that a single 25mg dose produced instant emotional breakthroughs and sustained neural plasticity compared to daily standard SSRI courses.
Double-blind, active-controlled clinical trial involving 233 participants with treatment-resistant depressive conditions.
Rapid, robust, and sustained reduction in depressive symptoms over a 12-week course following isolated psilocybin administration.
Microdosing Psilocybin Stacks: Longitudinal Behavioral Analysis of Flow States
This study evaluated the behavioral impacts of scheduled microdosing stacks. Participants reported substantial upgrades in daily problem-solving focus, acute task absorption (flow states), and a significant decrease in daily stress markers.
Longitudinal self-report study tracking 1,028 microdose practitioners utilizing the Fadiman Protocol over 6 weeks.
Sub-perceptual microdoses (0.1g) significantly elevate daily theta brainwave cycles, promoting focus and creativity.
Neurogenesis and Synaptic Mapping Induced by Tryptamine Alkaloids
This biological research investigated the direct molecular impacts of active tryptamine compounds on brain neural networks. The research proved that active psilocin binds to 5-HT2A receptors to spark dendritic branching, repairing compromised stress connections.
In-vitro cellular synaptic mapping and molecular signaling observation inside certified laboratory facilities.
Psilocin molecules actively stimulate Brain-Derived Neurotrophic Factor (BDNF) receptors, promoting neural dendritic growth.
Clinical Research FAQs
Get detailed mycological answers regarding clinical studies, neuroplasticity details, and therapeutic standards.
Neuroplasticity is the brain's capacity to reorganize itself by growing new neural connections and dendrites. Psilocybin acts as a powerful serotonin receptor agonist, stimulating Brain-Derived Neurotrophic Factor (BDNF), which rebuilds synaptic links damaged by stress.
A microdose (typically 50mg-200mg) contains psilocybin levels below the threshold of visual hallucinations. The active compounds raise cellular focus and mood indicators without altering your cognitive focus, making it fully safe for everyday routines.
Numerous longitudinal studies in psychopharmacology show that scheduled microdosing (like the Fadiman protocol) modulates the Default Mode Network (DMN) in the brain, decreasing hyperactive cortisol/stress outputs and lowering general anxiety.
Related Guides & Stacks
Subscribe To Our Newsletter
Join over 50,000+ Canadian subscribers. Receive clinical dosage guides, promotion discount coupons, and rare strain drop alerts directly to your inbox.